Atorvastatin banned by the UP State Medical Supplies Corporation

The UP state government banned to use substandard cardiac medicine “Atorvastatin” and recalls from govt hospitals. Medicine was supplied to over 160 government hospitals in Uttar Pradesh, failed on quality parameters fixed under Indian Pharmacopoeia.  WIth taking immediate action, the UP State Medical Supplies Corporation banned the use of the medicine. 

Atorvastatin is commonly prescribed medicine to treat cardiac ailments, but after it failed quality parameters, an order to recall the entire supply of the medicine has also been issued.

A notice has been issued to the Hyderabad-based supplier firm. The government also ensures to make arrangements to supply additional stock to accomplish the high demand for medicine. Health officials also said that the supplied samples of the medicine were previously approved and tested by the Regional Drugs Testing Laboratory (RDTL) Chandigarh and only then supply orders were passed on November 19. 

Random testing results in substandard, when samples picked from district hospital Agra and sent for testing again. And new assessment report by the Chandigarh-based lab said the sample does not conform to the claim as per IP with respect to dissolution and therefore was not found to be of the standard quality.

Atorvastatin is used to treat cardiac ailments as it helps to lower bad cholesterol and fats such as triglycerides and raise good cholesterol in the blood.

A cardiologist, Prof Aditya Kapoor at  Sanjay Gandhi Post Graduate Institute of Medical Science (SGPGIMS) shared that the Atorvastatin belongs to a group of drugs known as statin and works by reducing the amount of cholesterol made by the liver. Its intake under medical supervision is important to prevent stroke and heart attacks.

This medicine is in huge demand as the Shyama Prasad Mukherjee Civil Hospital in Lucknow alone, needs about 25,000 tablets of the medicine every month. The demand for a year jumps to three lakh units.

Related Posts

Gene Therapy for Cholesterol: Initial Test Results Cheer

Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gene Therapy for Cholesterol: Initial Test Results Cheer

Gene Therapy for Cholesterol: Initial Test Results Cheer

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states